Dendreon Corp. Hit Publics Market on The Wall Street on Television Today --- Dendreon Corp. Hit Publics Market on The Wall Street. Dendreon Corp. (DNDN US) gained as much as 19 percent to $47.32 before trading was halted, pending incoming news. The Seattle-based drug company won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators.
The Wall Street Transcript has recently published its Biotechnology & Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This Special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers.
The approval is a major milestone for Dendreon, the tiny biotechnology company that developed the treatment based on basic research that occurred at Stanford University. Dendreon shares, which have risen more than 200% in the past year, blasted up another 6% to $45 when news of the approval crossed the wire. Then they were halted. When trading restarted, shares were up 31%, to $52.
The FDA approved Provenge for patients whose prostate cancer has spread into their bodies; who have either no symptoms or minimal symptoms from the disease; and who won't respond to hormone blocking drugs. About 25,000 patients fall into this category each year. The package insert for the medicine, on which Dendreon's marketing will be based, contains few major warnings about serious side effects (patients get fevers and chills) or caveats about the product's effectiveness. Provenge will cost $93,000 per course of treatment.
Tags: provenge, dndn, sirius, bidu, fslr
The Wall Street Transcript has recently published its Biotechnology & Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This Special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers.
The approval is a major milestone for Dendreon, the tiny biotechnology company that developed the treatment based on basic research that occurred at Stanford University. Dendreon shares, which have risen more than 200% in the past year, blasted up another 6% to $45 when news of the approval crossed the wire. Then they were halted. When trading restarted, shares were up 31%, to $52.
The FDA approved Provenge for patients whose prostate cancer has spread into their bodies; who have either no symptoms or minimal symptoms from the disease; and who won't respond to hormone blocking drugs. About 25,000 patients fall into this category each year. The package insert for the medicine, on which Dendreon's marketing will be based, contains few major warnings about serious side effects (patients get fevers and chills) or caveats about the product's effectiveness. Provenge will cost $93,000 per course of treatment.
Tags: provenge, dndn, sirius, bidu, fslr
